期刊文献+

葆宫止血颗粒联合地屈孕酮治疗功能失调性子宫出血的疗效观察 被引量:37

Clinical study on Baogong Zhixue Granules combined with dydrogesterone in treatment of dysfunctional uterine bleeding
原文传递
导出
摘要 目的观察葆宫止血颗粒联合地屈孕酮治疗功能性子宫出血的临床疗效。方法选取2017年7月-2018年12月电子科技大学医学院附属医院·成都市妇女儿童中心医院收治的功能失调性子宫出血患者106例,随机分为对照组和治疗组,每组各53例。对照组患者月经来潮第5天开始对照组口服地屈孕酮片,10 mg/次,2次/d,自血止日算起,连服22 d,停药后待月经来潮第5天开始进行下一周期治疗。治疗组在对照组治疗基础上口服葆宫止血颗粒,1袋/次,2次/d。两组均连续治疗3个月经周期。观察两组的临床疗效,比较两组止血时间、子宫内膜厚度的变化情况。结果治疗后,对照组和治疗组的总有效率分别是73.58%、90.57%,两组比较差异具有统计学意义(P<0.05)。治疗后,治疗组患者止血时间明显短于对照组,两组比较差异具有统计学意义(P<0.05)。治疗后,两组患者子宫内膜厚度均显著降低,同组治疗前后比较差异有统计学意义(P<0.05);治疗后,治疗组子宫内膜厚度小于对照组,两组比较差异有统计学意义(P<0.05)。结论葆宫止血颗粒联合地屈孕酮治疗功能性子宫出血具有较好的临床疗效,可缩短患者的止血时间,改善子宫内膜厚度,具有一定的临床推广应用价值。 Objective To observe the clinical efficacy of Baogong Zhixue Granules combined with dydrogesterone in treatment of dysfunctional uterine bleeding. Method 106 Patients with dysfunctional uterine bleeding in UESTC Chengdu Women’s and Children’s Central Hospital from July 2017 to December 2018 were randomly divided into control(53 cases) and treatment(53 cases) groups. Patients in the control group were po administered with Dydrogesterone Tablets from the 5th day of menstruation, 10 mg/time, twice daily. From the date of stopping blood, they were treated for 22 d. After stopping the drug, the next cycle of treatment should be started on the 5th day after the onset of menstruation. Patients in the treatment group were po administered with Baogong Zhixue Granules, 1 bag/time, twice daily. Patients in two groups were treated for 3 consecutive menstrual cycles. After treatment, the clinical efficacy was evaluated, and hemostatic time and endometrial thickness in the two groups were compared. Result After treatment, the clinical efficacy in the control and treatment groups were 73.58% and 90.57%, respectively, and there were differences between two groups(P < 0.05). After treatment, the hemostasis time in the treatment group was significantly shorter than that in the control group, and there were differences between two groups(P < 0.05). After treatment, endometrial thickness in two groups was significantly reduced, and there were differences in the same group(P < 0.05). After treatment, endometrial thickness in the treatment group was lower than that in the control group, and there were differences between two groups(P < 0.05). Conclusion Baogong Zhixue Granules combined with dydrogesterone has effect in treatment of dysfunctional uterine bleeding, and can shorten the hemostasis time ofpatients, and also can improve the endometrial thickness, which has a certain clinical application value.
作者 万德花 连艳丽 蔡一铃 万虹 WAN De-hua;LIAN Yan-li;CAI Yi-ling;WAN Hong(Affiliated Hospital of Electronic Science and Technology University, UESTC Chengdu Women’s and Children’s Central Hospital, Chengdu 610000, China;Department of Gynecology, Sichuan Provincial for Women and Children, Chengdu 610000, China)
出处 《现代药物与临床》 CAS 2019年第8期2425-2427,共3页 Drugs & Clinic
关键词 葆宫止血颗粒 地屈孕酮片 功能性子宫出血 止血时间 子宫内膜厚度 Baogong Zhixue Granules Dydrogesterone Tablets dysfunctional uterine bleeding hemostatic time endometrial thickness
  • 相关文献

参考文献5

二级参考文献84

  • 1黄雪坤,尚慧玲,张四友,李光仪.促性腺激素释放激素激动剂联合监测排卵治疗子宫腺肌症合并不孕症的疗效观察[J].中华临床医师杂志(电子版),2011,5(11):3326-3328. 被引量:7
  • 2Bureh D, Bieshuevel E, Smith S, et al. Can endometrial protection be inferred from the bleeding pattern on combined cyclical hormone replacement therapy [ J ]. Maturitas, 2000, 34 (2) : 155 - 160.
  • 3Sator MO, Nagele F, Sator P, et al. Clinical profile of a new hormone replacement therapy containing 2 mg 17 beta - estradiol and 10 mg dydrogesterone [J]. Maturitas, 2000, 34(3) :267 - 273.
  • 4Bergeron C, Ferenczy A. Endometrial safety of continuous combined hormone replacement therapy with 17 beta - oestradiol (1 or 2 nag) dydrogesterone [ J ]. Maturitas, 2001, 37 (3) : 191 - 199.
  • 5Quereux C, Pomel B, Bergeron C, el al. Continuous combined hormone replacement therapy with 1 mg 17 beta - oestradiol and 5 mg dydrogesterone (Femoston (R) - conti ) : Endometrial safety and bleeding profile [J]. Maturitas, 2006, 53 ( 3 ) : 299 - 305.
  • 6De Franciscis P, Cobellis L, Fomaro F, et al. Low-dose hormone therapy in the perimenopause [J]. International Journal of Gynecology & Obstetrics, 2007, 98 (2) : 138 - 142.
  • 7Di Carlo C, Sammartino A, Sardo AD, et al. Bleeding patterns during continuous estradiol with different sequential progestogens therapy [ J ]. Menopause -the Journal of the North American Menopause Society, 2005, 12(5) :520 -525.
  • 8Adiyono W, Hardian. TNF -alpha and IL- 8 profile after dydrogesterone therapy on dysfunctional uterine bleeding patients. Third World Congress on Controversies in Obstetrics Gynecology & Infertility [ C ]. 2002 : 11 - 4
  • 9Foumier A, Berrino F, Clavel- Chapelon F, Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3 N cohort study [ J ]. Breast Cancer Research and Treatment, 2008, 107( 1 ) :103 - 11.
  • 10Campagnoli C, Abba C, Ambroggio S, et al. Differential effects of various progestogens on metabolic risk factors for breast cancer [J]. Gynecological Endocrinology, 2007, 23 ( S1 ) :22 - 31.

共引文献410

同被引文献353

引证文献37

二级引证文献233

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部